Search
Displaying 21–30 of 704 results
-
Gene Knock-Out, Replacement Therapy for RP-RHO Performed Well in Lab Study
Eye On the Cure Research NewsEditas is planning IND-enabling studies of the two-part treatment in preparation for a clinical trial
-
Promising Results from Lab Study of Gene Therapy for Cone-Rod Dystrophy
Eye On the Cure Research NewsThe study is an important step toward a clinical trial of the approach
-
Encouraging Clinical Trial Results for Alkeus’ Stargardt Disease Treatment
Eye On the Cure Research NewsThe company is also conducting a Phase 3 clinical trial of the emerging therapy for geographic atrophy.
-
Live Stream: XLRP-Patient Focused Drug Development
Landing PageThe live meeting will be to educate FDA staff and other key stakeholders such as biotech and pharmaceutical companies about what it is like to live with XLRP, with perspectives from both affected individuals as well as caregivers and family members of affected individuals.
-
XLRP-Patient Focused Drug Development
Landing PageThe goal of the June 7th meeting will be to educate FDA staff and other key stakeholders such as biotech and pharmaceutical companies about what it is like to live with XLRP, with perspectives from both affected individuals as well as caregivers and family members of affected individuals.
-
The Karen And Basil Petrou Legacy Education Initiative
Landing PageThe Basil and Karen Petrou Education Initiative is born of the Foundation’s commitment to helping individuals ensure their estates do the best they can for their loved ones and the causes they care about. Debuting this year, the program will offer ongoing resources to help individuals and families explore and learn about end-of-life plans and strategies.
-
“Great Vision Does Not Require Great Sight”
Beacon StoriesKenyetta has worked to help others through the nonprofit sector for over 25 years, despite being diagnosed with Stargardt disease at the age of 31. Kenyetta is now the chief operating officer of REACH Riverside Development Corporation and has been recognized for her career achievements by many.
-
Webinar for the X-Linked Retinitis Pigmentosa (XLRP) Community
Science EducationThe Foundation Fighting Blindness recently held a webinar to provide details about an upcoming Externally-Led Patient Focused Drug Development (EL-PFDD) meeting for XLRP, and to provide background information about the Food and Drug Administration’s (FDA) drug review process.
-
Foundation Summit Highlights Robust Growth in Commercial Development for Retinal Disease Therapies
Foundation NewsThe Foundation’s Investing in Cures Summit (ICS), held on April 2, 2022, in Half Moon Bay, California, convened 175 researchers, industry executives, and constituents to present and discuss the expanding and accelerating commercial development of emerging therapies for retinal degenerative diseases.
-
Age-Related Macular Degeneration Research Advances
Retinal Disease Research AdvancesRecent developments in research on age-related macular degeneration.
